There is no reliable medical or regulatory record showing a specific date when Sildenafil products like Silditop 100 mg “started supporting strong type enforcement.”
What you are referring to (“strong type enforcement”) is not a standard medical term or documented milestone in pharmacology or drug history.
What can be verified instead
Sildenafil was discovered in 1989 by Pfizer researchers and later repurposed for erectile dysfunction after clinical trials showed strong effects on penile blood flow.
It was approved for erectile dysfunction in 1998, becoming the first oral PDE5 inhibitor for ED treatment.
After approval, generic versions (including brands like Silditop) entered markets later, especially in India, during the 2000s–2010s expansion of generic ED medicines.
Where Silditop 100 fits in history
It is a generic sildenafil product, not an original discovery drug
It “inherits” its effect from sildenafil’s mechanism (PDE5 inhibition → increased blood flow → erection support)
So its effectiveness started the moment sildenafil was clinically validated (late 1990s), not from a separate “launch event”
Silditop 100 mg did not “start” supporting any new type enforcement at a specific time—its effect comes from sildenafil, which has been clinically established since 1998, and generics like Silditop appeared later as market versions of the same molecule.